Morbus Crohn

Der Morbus Crohn, der gemeinsam mit der Colitis ulcerosa zu den chronisch entzündlichen Darmerkrankungen gehört, tritt häufig in jungem Lebensalter erstmalig auf und verläuft dann schubförmig. Je nach Ausprägung der Erkrankung sind die Patienten in Lebensqualität und Gestaltung des persönlichen Lebenswegs teilweise stark eingeschränkt. Der hier vorliegende Beitrag gibt einen Überblick über Diagnostik und Therapie der Erkrankung.

Schlüsselwörter

Morbus Crohn - Remissionserhaltung - TNF-Antikörper - Komplikationen - Schwangerschaft

• Literatur

• 1 Molodecky NA, Soon IS, Rabi DM. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42 quiz e30
• 2 Ng SC, Kaplan GG, Tang W. et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol 2019; 114: 107-115
• 3 Franke A, McGovern DP, Barrett JC. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohnʼs disease susceptibility loci. Nat Genet 2010; 42: 1118-1125
• 4 Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol 2016; 11: 127-148
• 5 Kronman MP, Zaoutis TE, Haynes K. et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130: e794-e803
• 6 Sorensen LT, Malaki A, Wille-Jorgensen P. et al. Risk factors for mortality and postoperative complications after gastrointestinal surgery. J Gastrointest Surg 2007; 11: 903-910
• 7 Silverberg MS, Satsangi J, Ahmad T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A) 5A-36A
• 8 Manganelli C, Turco S, Balestrazzi E. Ophthalmological aspects of IBD. Eur Rev Med Pharmacol Sci 2009; 13 (Suppl. 01) 11-13
• 9 Preiss JC, Bokemeyer B, Buhr HJ. et al. [Updated German clinical practice guideline on “Diagnosis and treatment of Crohnʼs disease” 2014]. Z Gastroenterol 2014; 52: 1431-1484
• 10 Authors, Collaborators. [Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) – AWMF Registry 021/009]. Z Gastroenterol 2018; 56: 1087-1169
• 11 Gomollon F, Dignass A, Annese V. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohnʼs Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11: 3-25
• 12 Marits P, Landucci L, Sundin U. et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014; 8: 881-889
• 13 Jorgensen KK, Olsen IC, Goll GL. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389: 2304-2316
• 14 Feagan BG, Sandborn WJ, Gasink C. et al. Ustekinumab as induction and maintenance therapy for Crohnʼs disease. N Engl J Med 2016; 375: 1946-1960
• 15 Sands BE, Feagan BG, Rutgeerts P. et al. Effects of vedolizumab induction therapy for patients with Crohnʼs disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618-627.e3
• 16 Gionchetti P, Dignass A, Danese S. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohnʼs Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis 2017; 11: 135-149
• 17 Panes J, Garcia-Olmo D, Van Assche G. et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohnʼs disease. Gastroenterology 2018; 154: 1334-1342.e4